{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:09:25Z","timestamp":1794568165761,"version":"4.9.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["SAF-94814"],"award-info":[{"award-number":["SAF-94814"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While there has been extensive attention to the \u2018demand side\u2019 \u2013 or use and adverse consequences, including mortality \u2013 of the \u2018opioid crisis\u2019 presently unfolding across North America, few considerations have focused on the supply side. This paper examines the supply side dynamics of this unprecedented public health phenomenon. We provide evidence for several interrelated supply-side elements that have contributed to the present public health crisis. We observe that initially, persistently high levels of prescription opioid availability and use exposed large proportions of the North American population to opioids, resulting in correspondingly high levels of medical and non-medical use (e.g., involving diversion). While various intervention measures to control prescription opioid availability and use have been implemented in recent years, leading to eventual reductions in opioid dispensing levels, these occurred late in the crisis\u2019s evolution. Moreover, these supply reductions have not been met by corresponding reductions in opioid use or demand levels. These growing discrepancies between opioid demand and prescription-based sources have left major gaps in opioid supplies. In response to such supply gaps, highly potent and toxic illicit opioid products have rapidly proliferated across North America, and become a core driver of the dramatic spikes in opioid overdose fatality levels in recent years. These supply-related interrelations are corroborated by a corresponding increase in illicit opioid-related fatalities, which arose just as medical opioid supplies began to decrease in many jurisdictions. Improved analyses and understanding of the supply-side dynamics of the opioid crisis are urgently needed in order to inform future intervention and policy development. Meanwhile, the high mortality toll related to illicit, highly toxic opioid exposure requires sustained solutions, including supply-oriented measures (e.g., safer opioid distribution for at\u2013risk users) towards improved public health protection.<\/jats:p>","DOI":"10.1186\/s13011-020-0256-8","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T11:09:04Z","timestamp":1581937744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-4030","authenticated-orcid":false,"given":"Benedikt","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"256_CR1","unstructured":"Center for Disease Control and Prevention. National Center for Health Statistics: Provisional Opioid Overdose Death Counts. 2019 Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"key":"256_CR2","unstructured":"Health Canada. Overview of national data on opioid-related harms and deaths. 2018 Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/problematic-prescription-drug-use\/opioids\/data-surveillance-research\/harms-deaths.html. Retrieved on January 2, 2020."},{"issue":"49","key":"256_CR3","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1073\/pnas.1518393112","volume":"112","author":"A Case","year":"2015","unstructured":"Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"256_CR4","unstructured":"Public Health Agency of Canada. The Chief Public Health Officer\u2019s Report on the State of Public Health in Canada 2018: Preventing problematic substance use in youth. Public Health Agency of Canada (PHAC) 2018."},{"key":"256_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","volume":"36","author":"A Kolodny","year":"2015","unstructured":"Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559\u201374.","journal-title":"Annu Rev Public Health"},{"issue":"17\u201318","key":"256_CR6","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1503\/cmaj.160356","volume":"188","author":"B Fischer","year":"2016","unstructured":"Fischer B, Rehm J, Tyndall M. Effective Canadian policy to reduce harms from prescription opioids: learning from past failures. CMAJ. 2016;188(17\u201318):1240\u20134.","journal-title":"CMAJ."},{"issue":"17","key":"256_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMp1800216","volume":"378","author":"E Wood","year":"2018","unstructured":"Wood E. Strategies for reducing opioid-overdose deaths - lessons from Canada. N Engl J Med. 2018;378(17):1565\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"256_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJMp1615145","volume":"376","author":"RG Frank","year":"2017","unstructured":"Frank RG, Pollack HA. Addressing the fentanyl threat to public health. N Engl J Med. 2017;376(7):605\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"256_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annemergmed.2016.08.445","volume":"69","author":"SN Lucyk","year":"2017","unstructured":"Lucyk SN, Nelson LS. Novel synthetic opioids: an opioid epidemic within an opioid epidemic. Ann Emerg Med. 2017;69(1):91\u20133.","journal-title":"Ann Emerg Med"},{"key":"256_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ypmed.2017.11.001","volume":"107","author":"B Fischer","year":"2018","unstructured":"Fischer B, Vojtila L, Rehm J. The 'fentanyl epidemic' in Canada - some cautionary observations focusing on opioid-related mortality. Prev Med. 2018;107:109\u201313.","journal-title":"Prev Med"},{"key":"256_CR11","doi-asserted-by":"crossref","unstructured":"Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134(Pt A):121\u201332.","DOI":"10.1016\/j.neuropharm.2017.10.016"},{"key":"256_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","volume":"171","author":"J Suzuki","year":"2017","unstructured":"Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107\u201316.","journal-title":"Drug Alcohol Depend"},{"key":"256_CR13","unstructured":"BC Centre for Disease Control. Opioid Overdose Fact Sheet. 2018. Available from: http:\/\/www.bccdc.ca\/health-professionals\/data-reports\/overdose-response-reports. Retrieved: January 2, 2020."},{"key":"256_CR14","unstructured":"Alberta Health Services. Opioids and Substances of Misuse - Alberta Report, 2017 Q4. 2018."},{"key":"256_CR15","unstructured":"Hedegaard H, Minino AM, Warner M. Drug Overdose Deaths in the United States, 1999-2017. NCHS Data Brief 2018(329):1\u20138."},{"key":"256_CR16","unstructured":"National Institute on Drug Abuse. National Drug Overdose Deaths Involving Cocaine, by Opioid Involvement \u2013 Number Among All Ages, 1999\u20132017. National Institute on Drug Abuse (NIDA);2019. Available from: https:\/\/www.drugabuse.gov\/related-topics\/trends-statistics\/overdose-death-rates. Retreived on January 3, 2020."},{"key":"256_CR17","unstructured":"Duran EZ, B.C. marks 2017 as deadliest O.D. death year in provincial history. Global News. 2018."},{"issue":"3","key":"256_CR18","first-page":"593","volume":"28","author":"JP Caulkins","year":"1998","unstructured":"Caulkins JP. Reuter P. What Price Data Tell Us about Drug Markets. 1998;28(3):593\u2013612.","journal-title":"What Price Data Tell Us about Drug Markets"},{"issue":"4","key":"256_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1360-0443.2005.01000.x","volume":"100","author":"L Degenhardt","year":"2005","unstructured":"Degenhardt L, Reuter P, Collins L, Hall W. Evaluating explanations of the Australian 'heroin shortage'. Addiction. 2005;100(4):459\u201369.","journal-title":"Addiction."},{"issue":"1","key":"256_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1046\/j.1360-0443.2003.00248.x","volume":"98","author":"D Weatherburn","year":"2003","unstructured":"Weatherburn D, Jones C, Freeman K, Makkai T. Supply control and harm reduction: lessons from the Australian heroin 'drought'. Addiction. 2003;98(1):83\u201391.","journal-title":"Addiction."},{"key":"256_CR21","doi-asserted-by":"crossref","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. International Journal of Drug Policy. 2017;46:107\u201311.","DOI":"10.1016\/j.drugpo.2017.06.010"},{"key":"256_CR22","doi-asserted-by":"crossref","unstructured":"Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyls in the opioid street market: desired or imposed? Addiction. 2018;114(5):774\u201378.","DOI":"10.1111\/add.14474"},{"key":"256_CR23","doi-asserted-by":"crossref","unstructured":"Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician. 2012;15(3 Suppl):Es191\u2013203.","DOI":"10.36076\/ppj.2012\/15\/ES191"},{"key":"256_CR24","volume-title":"Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes - chapter II: narcotic drugs - availability of opioid analgesics","author":"International Narcotics Control Board","year":"2015","unstructured":"International Narcotics Control Board. Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes - chapter II: narcotic drugs - availability of opioid analgesics. 2015."},{"issue":"14","key":"256_CR25","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/jama.2015.11859","volume":"314","author":"B Han","year":"2015","unstructured":"Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA. 2015;314(14):1468\u201378.","journal-title":"JAMA."},{"issue":"1\u20132","key":"256_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.drugalcdep.2012.03.010","volume":"126","author":"B Nosyk","year":"2012","unstructured":"Nosyk B, Marshall BD, Fischer B, Montaner JS, Wood E, Kerr T. Increases in the availability of prescribed opioids in a Canadian setting. Drug Alcohol Depend. 2012;126(1\u20132):7\u201312.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"256_CR27","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1503\/cmaj.060729","volume":"175","author":"B Fischer","year":"2006","unstructured":"Fischer B, Rehm J, Patra J, Cruz MF. Changes in illicit opioid use across Canada. CMAJ. 2006;175(11):1385.","journal-title":"CMAJ."},{"issue":"9","key":"256_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/pds.1276","volume":"15","author":"LJ Paulozzi","year":"2006","unstructured":"Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618\u201327.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"256_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jama.2013.272","volume":"309","author":"CM Jones","year":"2013","unstructured":"Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657\u20139.","journal-title":"JAMA."},{"issue":"12","key":"256_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1503\/cmaj.090784","volume":"181","author":"IA Dhalla","year":"2009","unstructured":"Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181(12):891\u20136.","journal-title":"CMAJ."},{"issue":"4","key":"256_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/pds.3404","volume":"22","author":"B Fischer","year":"2013","unstructured":"Fischer B, Jones W, Rehm J. High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmacoepidemiol Drug Saf. 2013;22(4):438\u201342.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"26","key":"256_CR32","first-page":"563","volume":"63","author":"LJ Paulozzi","year":"2014","unstructured":"Paulozzi LJ, Mack KA, Hockenberry JM. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines - United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):563\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"256_CR33","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Helm S, 2nd, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):Es9\u201338.","DOI":"10.36076\/ppj.2012\/15\/ES9"},{"issue":"13","key":"256_CR34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, McLellan AT. Opioid abuse in chronic pain--misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253\u201363.","journal-title":"N Engl J Med"},{"issue":"2","key":"256_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.17269\/cjph.105.4143","volume":"105","author":"B Fischer","year":"2014","unstructured":"Fischer B, Gooch J, Goldman B, Kurdyak P. Rehm. Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later. Canadian Journal of Public Health. 2014;105(2):146\u20139.","journal-title":"Canadian Journal of Public Health"},{"issue":"3","key":"256_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1526-4637.2012.01327.x","volume":"13","author":"LM Reifler","year":"2012","unstructured":"Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse\/misuse? Pain Med. 2012;13(3):434\u201342.","journal-title":"Pain Med"},{"issue":"4","key":"256_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ajim.21998","volume":"55","author":"GM Franklin","year":"2012","unstructured":"Franklin GM, Mai J, Turner J, Sullivan M, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: impact of the Washington state opioid dosing guideline. Am J Ind Med. 2012;55(4):325\u201331.","journal-title":"Am J Ind Med"},{"issue":"3","key":"256_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/pds.3553","volume":"23","author":"HL Surratt","year":"2014","unstructured":"Surratt HL, O'Grady C, Kurtz SP, Stivers Y, Cicero TJ, Dart RC, et al. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol Drug Saf. 2014;23(3):314\u201320.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"26","key":"256_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","volume":"66","author":"GP Guy Jr","year":"2017","unstructured":"Guy GP Jr, Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697\u2013704.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"256_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.36076\/ppj.2018.3.219","volume":"21","author":"B Fischer","year":"2018","unstructured":"Fischer B, Jones W, Vojtila L, Kurdyak P. Patterns, changes, and trends in prescription opioid dispensing in Canada, 2005-2016. Pain Physician. 2018;21(3):219\u201328.","journal-title":"Pain Physician"},{"key":"256_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1472-6963-14-90","volume":"14","author":"B Fischer","year":"2014","unstructured":"Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions. BMC Health Serv Res. 2014;14:90.","journal-title":"BMC Health Serv Res"},{"key":"256_CR42","doi-asserted-by":"crossref","unstructured":"Schieber L, Guy G, Seth P, Young R, Mattson C, Milkosz C, et al. Trends and Patterns of Geographic Variation in Opioid Prescribing Practices by State, United States, 2006-2017. JAMA Network Open. 2019:2(3):e190665.","DOI":"10.1001\/jamanetworkopen.2019.0665"},{"issue":"4","key":"256_CR43","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.jpain.2013.01.455","volume":"14","author":"H Surratt","year":"2013","unstructured":"Surratt H, Kurtz S, Cicero T, Dart R, Baker G, Vorsanger G. Street prices of prescription opioids diverted to the illicit market: data from a national surveillance program. J Pain. 2013;14(4):S40.","journal-title":"J Pain"},{"key":"256_CR44","doi-asserted-by":"crossref","unstructured":"Severtson SG, Bartelson BB, Davis JM, Munoz A, Schneider MF, Chilcoat H, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. The Journal of Pain. 2013;14(10):1122\u201330.","DOI":"10.1016\/j.jpain.2013.04.011"},{"key":"256_CR45","doi-asserted-by":"crossref","unstructured":"Fischer B. Prescription opioid use, harms and interventions in Canada: a review update of new developments and findings since 2010. 2015;18:E605-E14.","DOI":"10.36076\/ppj.2015\/18\/E605"},{"issue":"1","key":"256_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugalcdep.2018.04.024","volume":"18","author":"B Fischer","year":"2018","unstructured":"Fischer B, Varatharajan T, Shield K, Rehm J, Jones WJ. Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug Alcohol Depend. 2018;18(1):76\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"256_CR47","doi-asserted-by":"crossref","unstructured":"Saloner B, Karthikeyan SJJ. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004\u20132013. JAMA. 2015;314(14):1515\u20137.","DOI":"10.1001\/jama.2015.10345"},{"key":"256_CR48","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell JK, Gladden RM, Seth PJ. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region\u2014United States, 2006\u20132015. Morbidity and Mortality Weekly Report. 2017;66(34):897.","DOI":"10.15585\/mmwr.mm6634a2"},{"key":"256_CR49","doi-asserted-by":"crossref","unstructured":"Gladden R. Fentanyl law enforcement submissions and increases in synthetic opioid\u2013involved overdose deaths\u201427 states, 2013\u20132014. MMWR. 2016;65.","DOI":"10.15585\/mmwr.mm6533a2"},{"key":"256_CR50","first-page":"k3207","volume":"362","author":"T Gomes","year":"2018","unstructured":"Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario. Canada. 2018;362:k3207.","journal-title":"Canada."},{"key":"256_CR51","unstructured":"BC Coroners Service. Fentanyl-Detected Illicit Drug Overdose Deaths: January 1, 2012 to September 30, 2018. British Columbia. 2018."},{"key":"256_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn N, Coffin PO, Walley M. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172\u20139.","journal-title":"Int J Drug Policy"},{"key":"256_CR53","doi-asserted-by":"crossref","unstructured":"Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG. Bucher-Bartelson B, et al. Trends in opioid analgesic abuse and mortality in the United States. NEJM. 2015;372(3):241\u20138.","DOI":"10.1056\/NEJMsa1406143"},{"issue":"2","key":"256_CR54","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra1508490","volume":"374","author":"WM Compton","year":"2016","unstructured":"Compton WM, Jones CM, Baldwin J. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154\u201363.","journal-title":"N Engl J Med"},{"key":"256_CR55","doi-asserted-by":"crossref","unstructured":"Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. \u201cEvery \u2018never\u2019I ever said came true\u201d: transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25(2):257\u201366.","DOI":"10.1016\/j.drugpo.2013.10.004"},{"key":"256_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.drugpo.2016.05.009","volume":"34","author":"K DeBeck","year":"2016","unstructured":"DeBeck K, Wood E, Dong H, Dobrer S, Hayashi K, Montaner J, et al. Non-medical prescription opioid use predicts injection initiation among street-involved youth. Internaional Journal of Drug Policy. 2016;34:96\u2013100.","journal-title":"Internaional Journal of Drug Policy"},{"issue":"10","key":"256_CR57","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/cid\/ciu643","volume":"59","author":"AG Suryaprasad","year":"2014","unstructured":"Suryaprasad AG, White JZ, Xu F, Eichler B-A, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012. J Clinical Infectious Diseases. 2014;59(10):1411\u20139.","journal-title":"J Clinical Infectious Diseases"},{"issue":"7","key":"256_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005419","volume":"4","author":"SE Hadland","year":"2014","unstructured":"Hadland SE, DeBeck K, Kerr T, Feng C, Montaner JS, Wood E. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open. 2014;4(7):e005419.","journal-title":"BMJ Open"},{"issue":"7","key":"256_CR59","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1360-0443.2012.03803.x","volume":"107","author":"J Bruneau","year":"2012","unstructured":"Bruneau J, Roy \u00c9, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318\u201327.","journal-title":"Addiction."},{"issue":"1","key":"256_CR60","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.2105\/AJPH.2012.300874","volume":"103","author":"JR Havens","year":"2013","unstructured":"Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44\u201352.","journal-title":"Am J Public Health"},{"key":"256_CR61","doi-asserted-by":"crossref","unstructured":"Peppin J, Coleman J. Characterization of prescription opioid abuse in the United States: focus on route of administration. Journal of Pain & Palliative Care Pharmacotherapy. 2012;26(4):348\u201361.","DOI":"10.3109\/15360288.2012.734905"},{"key":"256_CR62","unstructured":"BC Coroners Service. llicit Drug Overdose Deaths in B.C.: Findings of Coroners' Investigations. Vancouver: BC Coroners Service; 2018."},{"key":"256_CR63","doi-asserted-by":"crossref","unstructured":"Monico LB, Mitchell SG. Patient perspectives of transitioning from prescription opioids to heroin and the role of route of administration. Substance abuse treatment, prevention, policy. 2018;13(1):4.","DOI":"10.1186\/s13011-017-0137-y"},{"key":"256_CR64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drugpo.2015.12.021","volume":"28","author":"A Harocopos","year":"2016","unstructured":"Harocopos A, Allen B, Paone D. Circumstances and contexts of heroin initiation following non-medical opioid analgesic use in New York City. Int J Drug Policy. 2016;28:106\u201312.","journal-title":"Int J Drug Policy"},{"key":"256_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.drugalcdep.2017.03.011","volume":"176","author":"CM Jones","year":"2017","unstructured":"Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004\u20132013. Drug Alcohol Depend. 2017;176:89\u201395.","journal-title":"Drug Alcohol Depend"},{"key":"256_CR66","unstructured":"Centers for Disease Control and Prevention. U.S. Prescribing Rate Maps. 2018. https:\/\/www.cdc.gov\/drugoverdose\/ maps\/rxrate-maps.html. Accessed 24 Feb 2019."},{"key":"256_CR67","unstructured":"National Institute on Drug Abuse. Overdose Death Rates in 2018. 2018. https:\/\/www.drugabuse.gov\/related-topics\/trends-statistics\/ overdose-death-rates. Accessed 24 Feb 2019."},{"key":"256_CR68","unstructured":"Public Health Ontario. Rates of opioid-related mortality, Ontario, Canada, 2003\u20132017. British Columbia. 2018. https:\/\/www.publichealthontario.ca\/en\/data-and-analysis\/substance-use\/interactive-opioid-tool. Accessed 24 Feb 2019."},{"key":"256_CR69","unstructured":"British Columbia Coroners Service. Illicit drug overdose deaths and death rate per 100,000 population. 2019. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug.pdf. Accessed 24 Feb 2019."},{"issue":"5","key":"256_CR70","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.scijus.2018.04.004","volume":"58","author":"HE McKeown","year":"2018","unstructured":"McKeown HE, Rook TJ, Pearson JR, Jones OAH. Is Australia ready for fentanyl? Science & justice: Journal of the Forensic Science Society. 2018;58(5):366\u201371.","journal-title":"Science & justice: Journal of the Forensic Science Society"},{"issue":"1","key":"256_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.23907\/2017.004","volume":"7","author":"HE Schueler","year":"2017","unstructured":"Schueler HE. Emerging synthetic fentanyl analogs. Academic Forensic Pathology. 2017;7(1):36\u201340.","journal-title":"Academic Forensic Pathology"},{"key":"256_CR72","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugpo.2017.05.050","volume":"46","author":"L Beletsky","year":"2017","unstructured":"Beletsky L, Davis CS. Today's fentanyl crisis: Prohibition's Iron law, revisited. The International journal of drug policy. 2017;46:156\u20139.","journal-title":"The International journal of drug policy"},{"key":"256_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","volume":"134","author":"P Armenian","year":"2018","unstructured":"Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134:121\u201332.","journal-title":"Neuropharmacology."},{"issue":"12","key":"256_CR74","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/pds.2190","volume":"20","author":"B Fischer","year":"2011","unstructured":"Fischer B, Jones W, Krahn M, Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005\u20132010. Pharmacoepidemiol Drug Saf. 2011;20(12):1269\u201377.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"256_CR75","unstructured":"Canadian Institute for Health Information. Pan-Canadian Trends in the Prescribing of Opioids, 2012 to 2016. Ottawa, ON: Canadian Institute for Health Information (CIHI); 2017."},{"issue":"5","key":"256_CR76","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/bcp.12446","volume":"78","author":"B Blanch","year":"2014","unstructured":"Blanch B, Pearson SA, Haber P. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol. 2014;78(5):1159\u201366.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"256_CR77","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.drugpo.2014.07.009","volume":"25","author":"DF Weisberg","year":"2014","unstructured":"Weisberg DF, Becker WC, Fiellin DA. Stannard. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int J Drug Policy. 2014;25(6):1124\u201330.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"256_CR78","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.drugpo.2015.04.003","volume":"26","author":"J Mounteney","year":"2015","unstructured":"Mounteney J, Giraudon I, Denissov G. Griffiths. Fentanyls: are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015;26(7):626\u201331.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"256_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/187447370801150611184218","volume":"8","author":"J van Amsterdam","year":"2015","unstructured":"van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? Current Drug Abuse Reviews. 2015;8(1):3\u201314.","journal-title":"Current Drug Abuse Reviews"},{"key":"256_CR80","unstructured":"Garza A. Illicitly produced fentanyl: a growing cause of synthetic opioid deaths: pharmacy times; 2018. Available from: https:\/\/www.pharmacytimes.com\/publications\/issue\/2018\/august2018\/illegally-produced-fentanyl-a-growing-cause-of-synthetic-opioid-deaths. Accessed: January 2, 2020."},{"key":"256_CR81","volume-title":"Evolution of the U.S","author":"RAND","year":"2018","unstructured":"RAND. Evolution of the U.S. Understanding China's Role in the Production and Supply of Synthetic Opioids.: Overdose Crisis; 2018."},{"key":"256_CR82","doi-asserted-by":"crossref","unstructured":"Babor T, Caulkins J, Fischer B, Foxcroft D, Humphreys K, Medina-Mora ME, et al. Drug policy and the public good: Oxford University Press; 2018.","DOI":"10.1093\/oso\/9780198818014.001.0001"},{"issue":"4","key":"256_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1257\/pol.20170082","volume":"10","author":"A Alpert","year":"2018","unstructured":"Alpert A, Powell D, Pacula RL. Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids. Am Econ J Econ Pol. 2018;10(4):1\u201335.","journal-title":"Am Econ J Econ Pol"},{"key":"256_CR84","doi-asserted-by":"crossref","unstructured":"D\u2019Onofrio G, Chawarski MC, O\u2019Connor PG, Pantalon MV, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med 2017;32(6):660\u20136.","DOI":"10.1007\/s11606-017-3993-2"},{"issue":"4","key":"256_CR85","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/acem.12910","volume":"23","author":"EA Samuels","year":"2016","unstructured":"Samuels EA, Dwyer K, Mello MJ, Baird J, Kellogg AR, Bernstein E. Emergency department-based opioid harm reduction: moving physicians from willing to doing. Acad Emerg Med. 2016;23(4):455\u201365.","journal-title":"Acad Emerg Med"},{"key":"256_CR86","volume-title":"Drug and opioid-involved overdose deaths - United States, 2013\u20132017","author":"L Scholl","year":"2019","unstructured":"Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013\u20132017. Centre for Disease Control and Prevention: Atlanta, USA; 2019."},{"key":"256_CR87","unstructured":"Government of Canada. Opioid-related harms in Canada Ottawa, ON: Government of Canada; 2019. Available from: https:\/\/infobase.phac-aspc.gc.ca\/datalab\/national-surveillance-opioid-mortality.html. Accessed: January 2, 2020."},{"issue":"1","key":"256_CR88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"issue":"8","key":"256_CR89","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777\u201386.","journal-title":"N Engl J Med"},{"key":"256_CR90","doi-asserted-by":"crossref","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. J Cochrane Database of Systematic Reviews. 2010;8.","DOI":"10.1002\/14651858.CD003410.pub3"},{"key":"256_CR91","doi-asserted-by":"crossref","unstructured":"Fischer B, Pang M, Tyndall M. Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps. J Public Health. 2019:fdz162.","DOI":"10.1093\/pubmed\/fdz162"},{"issue":"2","key":"256_CR92","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1503\/cmaj.171060","volume":"190","author":"M Tyndall","year":"2018","unstructured":"Tyndall M. An emergency response to the opioid overdose crisis in Canada: a regulated opioid distribution program. CMAJ. 2018;190(2):E35\u2013e6.","journal-title":"CMAJ."},{"issue":"2","key":"256_CR93","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S2468-2667(18)30232-9","volume":"4","author":"B Fischer","year":"2019","unstructured":"Fischer B, Pang M, Tyndall M. The opioid death crisis in Canada: crucial lessons for public health. Lancet Public Health. 2019;4(2):e81\u2013e2.","journal-title":"Lancet Public Health"},{"issue":"2","key":"256_CR94","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.puhe.2008.10.006","volume":"123","author":"B Fischer","year":"2009","unstructured":"Fischer B, Gittins J, Kendall P, Rehm J. Thinking the unthinkable: could the increasing misuse of prescription opioids among street drug users offer benefits for public health? Public Health. 2009;123(2):145\u20136.","journal-title":"Public Health"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-0256-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13011-020-0256-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-0256-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T16:04:25Z","timestamp":1665849865000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-020-0256-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1186\/s13011-020-0256-8","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}